Patients with Barrett’s Esophagus are at a higher risk to develop esophageal cancer, but it has always been challenging for physicians to determine which of their patients are at greatest risk.

Dr. Michael Weinstein interviews Dr. Matthew Goldberg, who is medical director of Castle Biosciences about TissueCypher, a test to help gastroenterologists stratify risk for cancer in patients with Barrett's Esophagus.

Join Dr. Weinstein and Dr. Goldberg to hear about how this innovative test can help gastroenterologists and pathologists better identify those patients who are most at risk and provide the appropriate care to help prevent them from developing esophageal cancer.

Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

Mixed and mastered by Hayden Margolis

Gastro Broadcast, Episode 50